GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Has Average Target Price of $4.23 According to Brokerages

Key Points

• Analysts maintain a “Hold” consensus on GoodRx, with three sell, six hold, and four buy ratings. The average 12-month price target is $4.23, above the stock’s reported $3.28 opening price.
• Recent analyst views were mixed: TD Cowen raised its target to $5.00 and issued a buy rating, while Goldman Sachs and UBS retained neutral ratings with targets of $4.00 and $3.75, respectively.
• GoodRx met quarterly EPS expectations at $0.08 and exceeded revenue estimates with $200.4 million, although revenue declined 1.3% year over year. Insiders have sold approximately 2.76 million shares over the past 90 days.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has been given a consensus recommendation of "Hold" by the thirteen research firms that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $4.23.

Several analysts recently weighed in on the company. The Goldman Sachs Group reissued a "neutral" rating and set a $4.00 price target on shares of GoodRx in a report on Friday, August 7th. Weiss Ratings upgraded GoodRx from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday, August 7th. TD Cowen lifted their target price on GoodRx from $4.00 to $5.00 and gave the stock a "buy" rating in a report on Tuesday, August 11th. Leerink Partners set a $5.00 target price on GoodRx in a report on Thursday, August 6th. Finally, UBS Group boosted their target price on shares of GoodRx from $2.50 to $3.75 and gave the company a "neutral" rating in a research report on Thursday, August 13th.

GoodRx Stock Up 0.3%

Shares of GDRX opened at $3.28 on Friday. The firm has a market cap of $1.12 billion, a P/E ratio of 82.02, a price-to-earnings-growth ratio of 1.63 and a beta of 1.69. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.38 and a current ratio of 1.38. GoodRx has a 52 week low of $1.77 and a 52 week high of $5.81. The firm's 50-day simple moving average is $3.44 and its 200 day simple moving average is $2.87.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.08. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The firm had revenue of $200.41 million during the quarter, compared to the consensus estimate of $193.23 million. During the same period last year, the business posted $0.09 earnings per share. The business's revenue for the quarter was down 1.3% compared to the same quarter last year. On average, analysts forecast that GoodRx will post 0.16 earnings per share for the current year.

Insiders Place Their Bets

In other GoodRx news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of the business's stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $3.50, for a total value of $4,536,619.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders have sold 2,760,995 shares of company stock valued at $9,673,207. 5.87% of the stock is owned by insiders.

Institutional Investors Weigh In On GoodRx

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Technology Crossover Management X Ltd. bought a new stake in shares of GoodRx during the 2nd quarter valued at $4,762,000. Assenagon Asset Management S.A. raised its stake in GoodRx by 275.0% in the first quarter. Assenagon Asset Management S.A. now owns 517,576 shares of the company's stock valued at $1,014,000 after purchasing an additional 379,546 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in GoodRx during the second quarter worth about $540,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in GoodRx during the second quarter worth about $500,000. Finally, State of Wyoming increased its holdings in GoodRx by 280.4% in the 4th quarter. State of Wyoming now owns 192,701 shares of the company's stock valued at $522,000 after buying an additional 142,041 shares during the period. 63.77% of the stock is currently owned by institutional investors and hedge funds.

About GoodRx

GoodRx Holdings, Inc operates a healthcare technology platform that helps consumers find prescription medications at lower prices. Through its website and mobile applications, GoodRx allows users to compare prescription prices at participating pharmacies, access discount coupons and identify potential savings on commonly prescribed medications. The company's services are primarily focused on the United States.

GoodRx also offers GoodRx Gold, a membership program that provides additional discounts on eligible prescriptions, as well as telehealth services that connect consumers with healthcare providers for certain medical consultations and prescriptions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.